We are international
Donate
• health professionals TEXT SIZE   

For other announcements of interest to the medical community, choose a subcategory from the menu on the left.

IMF - Professionals
previous     next      view all

The Role of Vertebral Augmentation: Expert Opinions
An IMF Webcast that addresses frequently asked questions about kyphoplasty: Who is a good candidate? What clinical outcomes are you looking for? Can a patient receive kyphoplasty while undergoing chemo? How quickly have patients reported pain relief after the procedure.

International Myeloma Working Group
The Working Group, made up of 90 leading myeloma researchers, develops myeloma management guidelines aimed at providing patients with more durable remissions and a better quality of life. The Working Group's recent research has culminated in the publication of widely-used consensus statements.

New! A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop
Summaries from the workshop sessions in Kos, Greece on 5–30 June, 2007

Planning for Treatment With or Without Transplant
Balancing Efficacy, Toxicity, and Quality of Life for the Patient with Multiple Myeloma
Webcast of the Friday Satellite Symposium Preceding the 49th ASH Annual Meeting.

ASH 2007 WEBCASTS
We are pleased to present these webcasts of the 49th Annual American Society of Hematology Meeting (ASH) that was held in Atlanta, Georgia from December 8-11, 2007.

Global Clinical Trials Forum
Established by the International Myeloma Foundation, the U.S. Myeloma Forum is a committee of the nation’s leading multiple myeloma experts. The Forum’s goal is two-fold: to form a coalition that will work collaboratively on myeloma-related projects, and to avoid duplication of efforts and dilution of valuable resources by various cooperative groups working on myeloma trials in the United States.

THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA
BANK ON A CURE® DNA Data Base also finds Genetic Link to Bone Disease and Indications for Treatment

THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW FINDINGS REPORTED AT GLOBAL CANCER CONFERENCE REQUIRE NEW WAYS TO EVALUATE TREATMENTS
Survival and Longer Term Disease Control Take Precedence over Short Term Response to Treatment

New Clinical Practice Guideline Details Measures for Anticoagulant Use
A new ASCO Clinical Practice Guideline, "Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer," is now available, along with clinical tools and resources to help practicing oncologists and their colleagues implement the evidence-based recommendation in clinical settings.

Centers for Medicare and Medicaid Services (CMS) post "national coverage determination (NCD)" for coverage of erythropoiesis stimulating agents (ESAs).
Emerging safety concerns (thrombosis, cardiovascular events, tumor progression, and reduced survival) derived from clinical trials in several cancer and non-cancer populations prompted CMS to review its coverage of erythropoiesis stimulating agents (ESAs).

previous     next      view all